MIDI-SRS

K141046 · Srmc Co., Ltd. · ONG · Dec 24, 2014 · General, Plastic Surgery

Device Facts

• Record ID: K141046
• Device Name: MIDI-SRS
• Applicant: Srmc Co., Ltd.
• Product Code: ONG · General, Plastic Surgery
• Decision Date: Dec 24, 2014
• Decision: SESE
• Submission Type: Traditional
• Regulation: 21 CFR 878.4810
• Device Class: Class 2
• Attributes: Therapeutic

Intended Use

MiDi-SRS is intended for use in dermatological procedures requiring the coagulation of soft tissue.

Device Story

MiDi-SRS is a 1550nm Er-glass fiber laser surgical unit used in dermatology and general surgery. The device consists of a main body, tablet PC, foot switch, interlock switch, and key switch. It transforms laser energy into a split beam, creating microscopic treatment zones (MTZs) on the skin while leaving surrounding tissue intact. Operated by clinicians in a clinical setting, the device provides controlled thermal coagulation. The tablet PC interface allows the clinician to manage treatment parameters. The device benefits patients by enabling precise, fractional soft tissue coagulation for dermatological applications.

Clinical Evidence

No human clinical data. Evidence consists of bench testing (EN 60601-2-22, 60601-1, 60601-1-2) and in vivo porcine model studies. Porcine study measured MTZ width, depth, and lateral/depth thermal zones at 10mJ, 20mJ, and 30mJ energy levels across multiple time points (0, 3, 10, 15 days post-treatment) to confirm histological safety and efficacy.

Technological Characteristics

1550nm Er-glass fiber laser; fractional beam delivery; tablet PC interface; foot/interlock/key switches. Complies with EN 60601-1 (general safety), EN 60601-1-2 (EMC), and EN 60601-2-22 (laser surgical instruments).

Indications for Use

Indicated for dermatological procedures requiring soft tissue coagulation.

Regulatory Classification

Identification

(1) A carbon dioxide laser for use in general surgery and in dermatology is a laser device intended to cut, destroy, or remove tissue by light energy emitted by carbon dioxide.(2) An argon laser for use in dermatology is a laser device intended to destroy or coagulate tissue by light energy emitted by argon.

Predicate Devices

• SellaS by Dinona Company, Ltd. (K080382)

Submission Summary (Full Text)

{0}------------------------------------------------

Image /page/0/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a stylized depiction of an eagle or bird with three heads, representing the department's mission to protect the health of all Americans and provide essential human services. The words "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" are arranged in a circular fashion around the bird symbol.

Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002

December 23, 2014

SRMC Company, LTD % Ms. Priscilla Chung LK Consulting Group USA Incorporated 2651 East Chapman Avenue, Suite 110 Fullerton, California 92831

Re: K141046 Trade/Device Name: MiDi-SRS Regulation Number: 21 CFR 878.4810 Regulation Name: Laser surgical instrument for use in general and plastic surgery and in dermatology Regulatory Class: Class II Product Code: ONG and GEX Dated: November 26, 2014 Received: December 2, 2014

Dear Ms. Chung:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug. and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you; however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21

{1}------------------------------------------------

CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Industry and Consumer Education at its toll-free number [phone] or [phone] or at its Internet address

http://www.fda.gov/MedicalDevices/Resourcesfor You/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to

http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number [phone] or [phone] or at its Internet address

http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.

Sincerely yours,

# David Krause -S

for

Binita S. Ashar, M.D., M.B.A., F.A.C.S. Director Division of Surgical Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

{2}------------------------------------------------

## Indications for Use

510(k) Number (if known) K141046

Device Name MiDi-SRS

Indications for Use (Describe)

MiDi-SRS is intended for use in dermatological procedures requiring the coagulation of soft tissue.

Type of Use (Select one or both, as applicable)

X Prescription Use (Part 21 CFR 801 Subpart D)

| Over-The-Counter Use (21 CFR 801 Subpart C)

### CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

### *DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.*

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

> Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff [e-mail]

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

{3}------------------------------------------------

# 510(k) Summary (K141046)

This summary of 510(k)-safety and effectiveness information is being submitted in accordance with requirements of 21 CFR Part 807.92.

Date:

#### 1. Applicant / Submitter:

SRMC CO., LTD 7F, 1130, 2 Sunhwan-ro, Heungdeok-gu, Cheongju-si, Chungcheongbuk-do,361-825, Republic of KOREA

Tel: [phone] Fax: [phone]

#### 2. Submission Correspondent:

Priscilla Chung LK Consulting Group USA, Inc. 2651 E Chapman Ave Ste 110. Fullerton, CA 92831 Phone: [phone] Fax: [phone] Email: [e-mail]

#### 3. Device:

| Proprietary Name: | MiDi-SRS |
|------------------------------|-----------------------------------|
| Common Name: | Laser Surgical Unit |
| Classification Name: | Powered Laser Surgical Instrument |
| Classification: | Class II, 21 CFR 878.4810 |
| Classification Product Code: | ONG |

#### Predicate Device: 4.

SellaS by Dinona Company, Ltd. (K080382)

#### 5. Device Description:

MiDi-SRS is designed to provide laser energy (1550nm) for use in a variety of dermatology and general surgery procedures. The product consists of main body, a tablet PC, a foot switch, an interlock switch and a key switch. The device fires a 1550nm Er- glass Fiber laser beam which is

{4}------------------------------------------------

then split into a number of microscopic beams, producing tiny dot, or pixel-like treatment zones within the selected target area of the skin, leaving the other zones within it perfectly intact.

#### Intended Use: 6.

MiDi-SRS is intended for use in dermatological procedures requiring the coagulation of soft tissue.

#### 7. Performance Data(Non-Clinical):

Bench tests were performed according to EN 60601-2-22, 60601-1 and 60601-1-2 to evaluate its safety and EMC. All the test results met pre-set criteria and support substantial equivalence to the predicate devices.

In vivo animal testing using porcine models was also conducted to obtain histological data of values for depth and zone of ablation and thermal damage immediately post treatment; 3-5 days post treatment; and 10-14 days post treatment. The test results are as below and supports that the subject device would perform as well as the predicate device.

| Group /<br>Excision<br>days | Microscopic treatment zones (MTZs) | | | | |
|-----------------------------|------------------------------------|-----------------------------|--------------------------|------------------------|-----|
| | Measurement value (µm) | | | | |
| | Measured<br>width<br>(S.D.) | Measured<br>depth<br>(S.D.) | Thermal<br>zone: lateral | Thermal<br>zone: depth | |
| G1<br>0 | 10mJ | 17 | 17 | 151 | 205 |
| | 20mJ | 33 | 34 | 226 | 290 |
| | 30mJ | 29 | 36 | 277 | 325 |
| G2<br>3 | 10mJ | 17 | 64 | 19 | 57 |
| | 20mJ | 13 | 16 | 42 | 132 |
| | 30mJ | 3 | 10 | 32 | 104 |
| G3<br>10 | 10mJ | 0 | 0 | 0 | 0 |
| | 20mJ | 0 | 0 | 0 | 0 |
| | 30mJ | 0 | 0 | 0 | 0 |
| G4<br>15 | 10mJ | 0 | 0 | 0 | 0 |
| | 20mJ | 0 | 0 | 0 | 0 |
| | 30mJ | 0 | 0 | 0 | 0 |

#### 8. Substantial Equivalence

The MiDi-SRS is substantially equivalent to the predicate device in terms of indication for use and technology based on technical characteristics. The two devices are similar in the following

{5}------------------------------------------------

characteristics: intended use, spot size, wave length, aiming beam, power output, energy range, output mode, laser type, and beam mode. The major difference is in the user interface, however, the SW validation report provided in the submission supports that the touch screen tablet SW of the Midi-SRS is substantially equivalent to the predicate device in effectiveness.

#### 9. Conclusion:

Based on the substantial equivalence discussion and testing results, SRMC CO., LTD concludes that the MiDi-SRS is substantially equivalent to the predicate devices in safety and effectiveness.